Citation Impact
Citing Papers
Architecture of the Photosynthetic Oxygen-Evolving Center
2004 StandoutScience
Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
2011 Standout
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression
2019 Standout
Kaurane Diterpene, Kamebakaurin, Inhibits NF-κB by Directly Targeting the DNA-binding Activity of p50 and Blocks the Expression of Antiapoptotic NF-κB Target Genes
2002
Gastric cancer
2016 Standout
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Diterpenoids from Isodon species and their biological activities
2006 Standout
Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
1999 Standout
The evolving role of natural products in drug discovery
2005 Standout
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients
1998
Physical and mechanical properties of PLA, and their functions in widespread applications — A comprehensive review
2016 Standout
Inhibitory effect of indomethacin farnesil, a novel antiinflammatory prodrug, on carrgeenin-induced inflammation in rats
1990
Structure-based development of cathepsin L inhibitors and therapeutic applications for prevention of cancer metastasis and cancer-induced osteoporosis
2002
Contribution of platelets to tumour metastasis
2011 Standout
ROS in cancer therapy: the bright side of the moon
2020 Standout
The dual role of thymidine phosphorylase in cancer development and chemotherapy
2009
A new ent-kaurane diterpenoid from Rabdosia pseudo-irrorata
2001
Enhancement of T‐cell‐mediated anti‐tumour immunity via the ectopically expressed glucocorticoid‐induced tumour necrosis factor receptor‐related receptor ligand (GITRL) on tumours
2008 StandoutNobel
Antibacterial activity of ent‐kaurene diterpenoids from Rabdosia rosthornii
2004
Marine natural products
1990 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal Cancers
1999
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
1999 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Introduction of Fluorine and Fluorine‐Containing Functional Groups
2013 Standout
Basis for effective combination cancer chemotherapy with antimetabolites
2000
Podophyllotoxin, steganacin and combretastatin: Natural products that bind at the colchicine site of tubulin
1993
Homoharringtonine: A New Treatment Option for Myeloid Leukemia
2004
CYP2A6and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1
2008
Hydrogel nanoparticles in drug delivery
2008 Standout
The role of new agents in the treatment of non-small cell lung cancer
2002
Clinical potential of new antiestrogens.
1997
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Biodegradable polymeric nanoparticles based drug delivery systems
2009 Standout
Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae)
2007 Standout
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
2007 Standout
Phase I Study of Two Schedules of Oral S-1 in Combination with Fixed Doses of Oxaliplatin and Bevacizumab in Patients with Advanced Solid Tumors
2011
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen
1998 Standout
Anti-Tumor Effect of an Intratumoral Administration of Dendritic Cells in Combination with TS-1, an Oral Fluoropyrimidine Anti-Cancer Drug, and OK-432, a Streptococcal Immunopotentiator
2004
Antibacterial Activity of Trichorabdal A from Rabdosia trichocarpa Against Helicobacter pylori
1997
Laurene-type sesquiterpenes from the Red Sea red alga Laurencia obtusa as potential antitumor–antimicrobial agents
2012
11-Oxygenated cytotoxic 8,9-secokauranes from a New Zealand liverwort, Lepidolaena taylorii
1999
Drug discovery from medicinal plants
2005 Standout
Studies on the oridonin-loaded poly(d,l-lactic acid) nanoparticles in vitro and in vivo
2006
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study
2013
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study
2003
Kaurene Diterpene Induces Apoptosis in Human Leukemia Cells Partly through a Caspase-8-Dependent Pathway
2004
Caspase Inhibition Augmented Oridonin-Induced Cell Death in Murine Fibrosarcoma L929 by Enhancing Reactive Oxygen Species Generation
2008
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
New drugs in the treatment of colorectal carcinoma
1998
In vitro antitrypanosomal activity of plant terpenes against Trypanosoma brucei
2011 StandoutNobel
Traditional herbal medicine in Far-west Nepal: a pharmacological appraisal
2010
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
2011
Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer
2005
Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer
2000
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
2008 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Anthracycline Antibiotic Blockade of SV40 T Antigen Helicase Action
1998
Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies
2004
Monofluorination of Organic Compounds: 10 Years of Innovation
2015 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Ent-kaurenoids from Rabdosia umbrosa
1989
Preliminary experience with pure antiestrogens.
2001
5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies
2008
5-Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug Cytotoxicity
2007 StandoutNobel
Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review
2002
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
1994 Standout
Novel ent ‐Kaurane Diterpenoids from Isodon xerophilus
2001
Basic Guide to the Mechanisms of Antiestrogen Action
1998
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
1999 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Synthetic entry into the ent-kaurene framework. Application of an unprecedented transannular cyclization for forming the central bond common to the B and C rings
1997
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
Ent-kaurene diterpenoids from Rabdosia leucophylla
1998
ent-Kaurane Diterpenoids from Isodon angustifolius var. glabresecens
1997
Diterpenoid constituents from Rabdosia coetsa
1993
Diterpenoids from Rabdosia forrestii
1993
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
2014
The oral fluoropyrimidines in cancer chemotherapy.
1999
Bioactive Compounds and Antioxidant Activity in Different Types of Berries
2015 Standout
Plant Products as Antimicrobial Agents
1999 Standout
Attempts at the production of more selective antitumourals. Part III. Aziridinocyclophosphazenes linked to the polyamines 1,5-diaminopentane (cadaverine) and higher cousins
1987
Multicenter Phase II Trial of S-1 Plus Cisplatin in Patients With Untreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
2006
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
2012 Standout
Structural and Biochemical Studies of a Fluoroacetyl-CoA-Specific Thioesterase Reveal a Molecular Basis for Fluorine Selectivity
2010 StandoutNobel
Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors
2004
Phase I Pharmacokinetic Study of S-1 Plus Cisplatin in Patients With Advanced Gastric Carcinoma
2005
ent-Kaurane Diterpenoids from Isodon lungshengensis
1999
Fluorine in medicinal chemistry: A review of anti-cancer agents
2006
Direct Asymmetric Entry into the Cytotoxic 8,9-Secokaurene Diterpenoids. Total Synthesis of (−)-O-Methylshikoccin and (+)-O-(Methylepoxy)shikoccin
1996
Trends in the Aggressiveness of Cancer Care Near the End of Life
2004 Standout
A New Diterpenoid Isolated from Isodon japonica Structure Elucidation by NMR Spectroscopy
2002
Rubescensins S and T: Seco‐ent‐Kaurane Diterpenoids from Isodon rubescens var. taihangensis
2004
Drug Resistance in Cancer: An Overview
2014 Standout
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
2002 Standout
Taibaihenryiin C, a diterpenoid with a novel skeleton from Isodon henryi
2002
UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
1999
Works of Setsuo Takeda being referenced
STUDIES ON COMBINATION THERAPY WITH 1-(TETRAHYDRO-2-FURANYL)-5-FLUOROURACIL PLUS URACIL. II
1981
Antitumor Agents. I. DNA Topoisomerase II Inhibitory Activity and the Structural Relationship of Podophyllotoxin Derivatives as Antitumor Agents.
1992
TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors
1990
Interaction of DP-TAT-59, an active metabolite of new triphenylethylene-derivative (TAT-59), with estrogen receptors
1992
Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats
1996
Prolongation of survival period and improvement of cancer cachexia by long term administration of UFT
1996
Menogaril, an Anthracycline Compound with a Novel Mechanism of Action: Cellular Pharmacology
1990
Antitumor activities of harringtonine and homoharringtonine, cephalotaxus alkaloids which are active principles from plant by intraperitoneal and oral administration.
1982
Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice.
1997
Cytotoxic and Antitumor Activities ofRabdosiaDiterpenoids
1988
Effect of 1,3,3,5,5-pentaziridino-1-thia-2,4,6-triaza-3,5-diphosphorine-1-oxide, a new antitumor agent with inorganic ring, on various experimental tumors.
1982
Terpenoids. LIII. Antitumor activity of trichorabdals and related compounds.
1989
Pharmacological profiles of 2-carboxyphenyl-1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetate and 2-[(2-carboxyphenoxy)-carbonyl]phenyl-1-(4-chlorobenzoyl)-5-meth oxy-2- methylindole-3-acetate, new antiinflammatory agents.
1986
Terpenoids. L. Antitumor activity of diterpenoids from Rabdosia shikokiana var. occidentalis.
1985
Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.
1998
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
1996
Antitumor activity of diterpenoids, trichorabdals A,B, and C, and the related compounds: Synergism of two active sites.
1983